Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

Paul F. Schellhammer, Peter Venner, Gabriel P. Haas, Eric J. Small, Peter T. Nieh, D. Rusby Seabaugh, Anthony Patterson, Eric Klein, Zev Wajsman, Barry Furr, Yusong Chen, Geert J.C.M. Kolvenbag

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose: We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or bicalutamide for clinical progression or increasing PSA concentration in patients receiving combined androgen blockade for advanced prostate cancer. Materials and Methods: PSA concentrations were determined weekly for at least 6 weeks and then every other week for 6 weeks in 22 patients with stage D2 prostate cancer. All patients were withdrawn from antiandrogen therapy (8 flutamide and 14 bicalutamide) due to progression or an increasing PSA concentration. Objective response was evaluated before antiandrogen withdrawal and at week 12. Results: In 4 of 8 patients (50%) withdrawn from flutamide and 4 of 14 (29%) withdrawn from bicalutamide serum PSA concentrations decreased by 50% or more. PSA responses after withdrawal of flutamide therapy occurred within the first few days, whereas those after withdrawal of bicalutamide therapy occurred within 4 to 8 weeks. Of 4 patients assessed for objective response 2 had stable disease and 2 had progression. A PSA response was observed in the 2 patients with stable disease but not the 2 with progression. Conclusions: For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response. The time to PSA response is longer with bicalutamide than with flutamide. The clinical significance of the antiandrogen withdrawal phenomenon is unknown.

Original languageEnglish (US)
Pages (from-to)1731-1735
Number of pages5
JournalJournal of Urology
Volume157
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Flutamide
Androgen Antagonists
Prostate-Specific Antigen
Androgens
Therapeutics
Prostatic Neoplasms
bicalutamide
Disease Progression

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Schellhammer, P. F., Venner, P., Haas, G. P., Small, E. J., Nieh, P. T., Seabaugh, D. R., ... Kolvenbag, G. J. C. M. (1997). Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. Journal of Urology, 157(5), 1731-1735. https://doi.org/10.1016/S0022-5347(01)64846-8

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. / Schellhammer, Paul F.; Venner, Peter; Haas, Gabriel P.; Small, Eric J.; Nieh, Peter T.; Seabaugh, D. Rusby; Patterson, Anthony; Klein, Eric; Wajsman, Zev; Furr, Barry; Chen, Yusong; Kolvenbag, Geert J.C.M.

In: Journal of Urology, Vol. 157, No. 5, 01.01.1997, p. 1731-1735.

Research output: Contribution to journalArticle

Schellhammer, PF, Venner, P, Haas, GP, Small, EJ, Nieh, PT, Seabaugh, DR, Patterson, A, Klein, E, Wajsman, Z, Furr, B, Chen, Y & Kolvenbag, GJCM 1997, 'Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade', Journal of Urology, vol. 157, no. 5, pp. 1731-1735. https://doi.org/10.1016/S0022-5347(01)64846-8
Schellhammer, Paul F. ; Venner, Peter ; Haas, Gabriel P. ; Small, Eric J. ; Nieh, Peter T. ; Seabaugh, D. Rusby ; Patterson, Anthony ; Klein, Eric ; Wajsman, Zev ; Furr, Barry ; Chen, Yusong ; Kolvenbag, Geert J.C.M. / Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. In: Journal of Urology. 1997 ; Vol. 157, No. 5. pp. 1731-1735.
@article{cb0b256c49a541aeac8d4c58d72dc86e,
title = "Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade",
abstract = "Purpose: We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or bicalutamide for clinical progression or increasing PSA concentration in patients receiving combined androgen blockade for advanced prostate cancer. Materials and Methods: PSA concentrations were determined weekly for at least 6 weeks and then every other week for 6 weeks in 22 patients with stage D2 prostate cancer. All patients were withdrawn from antiandrogen therapy (8 flutamide and 14 bicalutamide) due to progression or an increasing PSA concentration. Objective response was evaluated before antiandrogen withdrawal and at week 12. Results: In 4 of 8 patients (50{\%}) withdrawn from flutamide and 4 of 14 (29{\%}) withdrawn from bicalutamide serum PSA concentrations decreased by 50{\%} or more. PSA responses after withdrawal of flutamide therapy occurred within the first few days, whereas those after withdrawal of bicalutamide therapy occurred within 4 to 8 weeks. Of 4 patients assessed for objective response 2 had stable disease and 2 had progression. A PSA response was observed in the 2 patients with stable disease but not the 2 with progression. Conclusions: For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response. The time to PSA response is longer with bicalutamide than with flutamide. The clinical significance of the antiandrogen withdrawal phenomenon is unknown.",
author = "Schellhammer, {Paul F.} and Peter Venner and Haas, {Gabriel P.} and Small, {Eric J.} and Nieh, {Peter T.} and Seabaugh, {D. Rusby} and Anthony Patterson and Eric Klein and Zev Wajsman and Barry Furr and Yusong Chen and Kolvenbag, {Geert J.C.M.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)64846-8",
language = "English (US)",
volume = "157",
pages = "1731--1735",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

AU - Schellhammer, Paul F.

AU - Venner, Peter

AU - Haas, Gabriel P.

AU - Small, Eric J.

AU - Nieh, Peter T.

AU - Seabaugh, D. Rusby

AU - Patterson, Anthony

AU - Klein, Eric

AU - Wajsman, Zev

AU - Furr, Barry

AU - Chen, Yusong

AU - Kolvenbag, Geert J.C.M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Purpose: We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or bicalutamide for clinical progression or increasing PSA concentration in patients receiving combined androgen blockade for advanced prostate cancer. Materials and Methods: PSA concentrations were determined weekly for at least 6 weeks and then every other week for 6 weeks in 22 patients with stage D2 prostate cancer. All patients were withdrawn from antiandrogen therapy (8 flutamide and 14 bicalutamide) due to progression or an increasing PSA concentration. Objective response was evaluated before antiandrogen withdrawal and at week 12. Results: In 4 of 8 patients (50%) withdrawn from flutamide and 4 of 14 (29%) withdrawn from bicalutamide serum PSA concentrations decreased by 50% or more. PSA responses after withdrawal of flutamide therapy occurred within the first few days, whereas those after withdrawal of bicalutamide therapy occurred within 4 to 8 weeks. Of 4 patients assessed for objective response 2 had stable disease and 2 had progression. A PSA response was observed in the 2 patients with stable disease but not the 2 with progression. Conclusions: For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response. The time to PSA response is longer with bicalutamide than with flutamide. The clinical significance of the antiandrogen withdrawal phenomenon is unknown.

AB - Purpose: We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or bicalutamide for clinical progression or increasing PSA concentration in patients receiving combined androgen blockade for advanced prostate cancer. Materials and Methods: PSA concentrations were determined weekly for at least 6 weeks and then every other week for 6 weeks in 22 patients with stage D2 prostate cancer. All patients were withdrawn from antiandrogen therapy (8 flutamide and 14 bicalutamide) due to progression or an increasing PSA concentration. Objective response was evaluated before antiandrogen withdrawal and at week 12. Results: In 4 of 8 patients (50%) withdrawn from flutamide and 4 of 14 (29%) withdrawn from bicalutamide serum PSA concentrations decreased by 50% or more. PSA responses after withdrawal of flutamide therapy occurred within the first few days, whereas those after withdrawal of bicalutamide therapy occurred within 4 to 8 weeks. Of 4 patients assessed for objective response 2 had stable disease and 2 had progression. A PSA response was observed in the 2 patients with stable disease but not the 2 with progression. Conclusions: For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response. The time to PSA response is longer with bicalutamide than with flutamide. The clinical significance of the antiandrogen withdrawal phenomenon is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0031001274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031001274&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)64846-8

DO - 10.1016/S0022-5347(01)64846-8

M3 - Article

VL - 157

SP - 1731

EP - 1735

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -